NEOVASC INC (NVCN) Stock Price, Forecast & Analysis
USA - NASDAQ:NVCN - CA64065J4037 - Common Stock
NVCN Key Statistics, Chart & Performance
The current stock price of NVCN is 30.03 USD. In the past month the price increased by 3.41%. In the past year, price increased by 212.49%.
NVCN Latest News, Press Relases and Analysis
NVCN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.45 | 221.04B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.45 | 205.11B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.75 | 151.88B | ||
| SYK | STRYKER CORP | 27.62 | 139.05B | ||
| IDXX | IDEXX LABORATORIES INC | 56.5 | 57.00B | ||
| BDX | BECTON DICKINSON AND CO | 13.11 | 54.18B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.14 | 50.00B | ||
| RMD | RESMED INC | 25.5 | 36.84B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.99 | 33.52B | ||
| PODD | INSULET CORP | 71.4 | 22.97B | ||
| DXCM | DEXCOM INC | 31.25 | 22.80B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Related stock screener links
About NVCN
Company Profile
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures, and markets products for the cardiovascular marketplace. The firm is engaged in the development of minimally invasive therapies in cardiovascular care: refractory angina and mitral valve regurgitation. Its products include the Neovasc Reducer (Reducer), for the treatment of refractory angina, and the Tiara (Tiara), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. The firm operates through one business segment: the development, manufacturing and marketing of medical devices. The firm's subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc. The firm carries its business in Canada, the United States and Europe.
Company Info
NEOVASC INC
Richmond, 5138-13562 Maycrest Way
Richmond British Columbia BRITISH COLUMBIA V6V 2J7 CA
CEO: Fred Colen
Employees: 71
Phone: 16042704344.0
NEOVASC INC / NVCN FAQ
What does NVCN do?
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures, and markets products for the cardiovascular marketplace. The firm is engaged in the development of minimally invasive therapies in cardiovascular care: refractory angina and mitral valve regurgitation. Its products include the Neovasc Reducer (Reducer), for the treatment of refractory angina, and the Tiara (Tiara), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. The firm operates through one business segment: the development, manufacturing and marketing of medical devices. The firm's subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc. The firm carries its business in Canada, the United States and Europe.
What is the current price of NVCN stock?
The current stock price of NVCN is 30.03 USD. The price increased by 1.66% in the last trading session.
Does NEOVASC INC pay dividends?
NVCN does not pay a dividend.
What is the ChartMill rating of NEOVASC INC stock?
NVCN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for NVCN stock?
NEOVASC INC (NVCN) currently has 71 employees.
NVCN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NVCN. When comparing the yearly performance of all stocks, NVCN is one of the better performing stocks in the market, outperforming 99.36% of all stocks.
NVCN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVCN. NVCN has a bad profitability rating. Also its financial health evaluation is rather negative.
NVCN Financial Highlights
Over the last trailing twelve months NVCN reported a non-GAAP Earnings per Share(EPS) of -105.01. The EPS decreased by -1143.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.81 |